Trials
1 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Eczema Atopic Dermatitis, Eczema, Atopic Dermatitis
- Main trialPhase 2/3
- “This is a Phase 2, two-stage, adaptive, 1:1 randomized, double-blind, vehicle-controlled clinical study evaluating the efficacy, safety, and tolerability of GX-03 topical ointment in adult subjects with atopic dermatitis (eczema). Stage 1 (Completed): Stage 1 comprised an initial cohort of 50 subjects evaluated through Week 8. Following a pre-specified interim analysis conducted under the supervision of Independent Data Monitoring Committee (IDMC), treatment-response patterns, safety profiles, and endpoint parameters were assessed to optimize enrollment criteria and outcome measures for…”In the company’s words, NCT07355075 on ClinicalTrials.gov
- Other names
- Hexagen Antimicrobial
Other drugs for Eczema Atopic Dermatitis
- ICP-332Beijing InnoCare Pharma Tech Co., Ltd. · Phase 3
- UpadacitinibAbbVie · Phase 3
- OPA-15406Otsuka · Phase 3
- MG-K10Shanghai Mabgeek Biotech.Co.Ltd · Phase 3
- VC005Jiangsu vcare pharmaceutical technology co., LTD · Phase 3
- StapokibartKeymed Biosciences Co.Ltd · Phase 3
Coming up1
- 20 Jan 2027Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Recruiting | 20 Jan 2027 | A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema) | |
| Phase 2Completed | 30 May 2021 | Safety and Efficacy of Intranasal Application of GX-03 as a Treatment and Prevention for COVID-19. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026